![[Toyota Times] From Strengthening Foundations to Boosting Productivity - Toyota Focuses on Break-Even Volume](https://businessfortnight.com/wp-content/uploads/2025/11/Toyota-Times-From-Strengthening-Foundations-to-Boosting-Productivity-Toyota-218x150.jpg "[Toyota Times] From Strengthening Foundations to Boosting Productivity – Toyota Focuses on Break-Even Volume")
CATANIA, Italy, Sept. 15, 2022 /PRNewswire/ — SIFI, a number one worldwide ophthalmic firm, broadcasts 3 scientific displays on its newest improvements throughout the upcoming Congress of The European Society of Cataract and Refractive Surgeons (ESCRS) which can happen from 16th to twentyth September in Milan (Italy). These displays will function the outcomes of research evaluating SIFI’s superior options for cataract refractive surgical procedure.
SIFI additionally broadcasts the launch of Evolux™, a novel prolonged monofocal intraocular lens (IOL), primarily based on a hydrophobic materials and a non-diffractive profile, designed to supply higher intermediate imaginative and prescient and equal distance imaginative and prescient when in comparison with a typical monofocal IOL. Evolux® was developed on a patented expertise platform, pioneering the extension of the depth of focus by wavefront engineering.
On Monday 19th September, the Free Paper “Visual Performance Of The Extended Depth Of Focus (Edof) Well Fusion® Optical System: Mini Well® On The Dominant Eye And Mini Well Proxa® On The Non-Dominant Eye After Cataract Surgery” (presenter: Dr. Victor Caparas) will showcase medical outcomes of SIFI’s first-in-kind distinctive resolution to deal with presbyopia.
The E-poster “Evolux, The New Standard Of Care With Extended Depth Of Focus In Monofocal Intraocular Lenses”. (E-poster quantity: PO192) will function preclinical outcomes evaluating the optical efficiency of SIFI’s new IOL Evolux™.
On Monday 19th September, the Satellite Symposium “Advanced solutions for targeting quantitative and qualitative outcomes in cataract refractive surgery: more possibilities for more patients” (presenters: Prof. Gerd U. Auffarth, Prof. Béatrice Cochener, Prof. Rita Mencucci, Prof. Emilio Pedrotti, Dr. Victor Caparas, Dr. Dorin Nicula), will function six displays addressing the position of amount and high quality of imaginative and prescient in cataract refractive surgical procedure, the medical outcomes of trials on the Well Fusion® optical system, the brand new prolonged monofocal IOL Evolux™ and the administration of postoperative therapy after cataract surgical procedure with Netildex® gel, a twice-a-day, preservative-free fastened mixture of dexamethasone 0.1% and netilmicin 0.3%.
SIFI’s crew seems to be ahead to welcoming ophthalmologists at Booth B28 to debate advantages and traits of the above merchandise, in addition to of Ecbirio™ and Amiriox™, two glaucoma medication lately launched in chosen European markets.
ABOUT WELL FUSION®
The WELL FUSION® system, by the mixture of the Mini Well® and the Mini WELL PROXA® intraocular lenses, supply a novel resolution that gives cataract sufferers the choice to deal with presbyopia with spectacle-free uninterrupted high-quality imaginative and prescient in any respect distances and in all lighting circumstances.
ABOUT EVOLUX™
Evolux™ is an prolonged monofocal IOL, primarily based on a hydrophobic materials and a non-diffractive profile designed to supply higher intermediate imaginative and prescient and equal distance imaginative and prescient when in comparison with a typical monofocal IOL.
ABOUT AMIRIOX™ and ECBIRIO™
Amiriox™ (bimatoprost 0.3 mg/ml) and Ecbirio™ (bimatoprost 0.3 mg/ml + timolol 5 mg/ml) are, respectively, the brand new monotherapy and glued mixture eye drops accredited for the discount of elevated intraocular stress in persistent open-angle glaucoma and ocular hypertension sufferers. Amiriox™ and Ecbirio™ can be found in a multi-dose preservative free presentation that helps to guard the ocular floor and ensures an extended in-use stability (as much as 90 days).
ABOUT SIFI
SIFI is a number one worldwide ophthalmic firm, headquartered in Italy, specializing in eye care since 1935. SIFI develops, manufactures, and markets progressive therapeutic options for sufferers with ophthalmic circumstances. SIFI is absolutely dedicated by its R&D to enhancing the standard of lifetime of sufferers, exporting remedies to greater than 20 international locations worldwide with a direct presence in Italy, Spain, France, Romania, Mexico, and Turkey.
Contacts: Sabrina Zappia
[email protected]
+393336999669
Logo – https://mma.prnewswire.com/media/1337809/SIFI_Logo.jpg
